{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:28:34Z","timestamp":1791106114744,"version":"4.1.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,6,23]],"date-time":"2007-06-23T00:00:00Z","timestamp":1182556800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1007\/s12035-007-0004-3","type":"journal-article","created":{"date-parts":[[2007,6,22]],"date-time":"2007-06-22T09:36:59Z","timestamp":1182505019000},"page":"82-91","source":"Crossref","is-referenced-by-count":76,"title":["Cannabinoids and Neuroprotection in Basal Ganglia Disorders"],"prefix":"10.1007","volume":"36","author":[{"given":"Onintza","family":"Sagredo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mois\u00e9s","family":"Garc\u00eda-Arencibia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"de Lago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Finetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Decio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Fern\u00e1ndez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,6,23]]},"reference":[{"key":"4_CR1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF03349186","volume":"29","author":"G Marsicano","year":"2006","unstructured":"Marsicano G, Lutz B (2006) Neuromodulatory functions of the endocannabinoid system J Endocrinol Invest 29:27\u201346","journal-title":"J Endocrinol Invest"},{"key":"4_CR2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/3-540-26573-2_16","volume":"168","author":"J Fern\u00e1ndez-Ruiz","year":"2005","unstructured":"Fern\u00e1ndez-Ruiz J, Gonz\u00e1lez S (2005) Cannabinoid control of motor function at the basal ganglia. Handb Exp Pharmacol 168:479\u2013507","journal-title":"Handb Exp Pharmacol"},{"key":"4_CR3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejphar.2003.08.101","volume":"480","author":"M Stelt van der","year":"2003","unstructured":"van der Stelt M, Di Marzo V (2003) The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol 480:133\u2013150","journal-title":"Eur J Pharmacol"},{"key":"4_CR4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0163-7258(02)00253-X","volume":"95","author":"J Romero","year":"2002","unstructured":"Romero J, Lastres-Becker I, de Miguel R, Berrendero F, Ramos JA, Fern\u00e1ndez-Ruiz JJ (2002) The endogenous cannabinoid system and the basal ganglia: biochemical, pharmacological and therapeutic aspects. Pharmacol Ther 95:137\u2013152","journal-title":"Pharmacol Ther"},{"key":"4_CR5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0009-3084(00)00193-6","volume":"108","author":"A Giuffrida","year":"2000","unstructured":"Giuffrida A, Piomelli D (2000) The endocannabinoid system: a physiological perspective on its role in psychomotor control. Chem Phys Lipids 108:151\u2013158","journal-title":"Chem Phys Lipids"},{"key":"4_CR6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/3-7643-7358-X_5","volume-title":"Cannabinoids as therapeutics (MDT)","author":"J Fern\u00e1ndez-Ruiz","year":"2005","unstructured":"Fern\u00e1ndez-Ruiz J, Gonz\u00e1lez S, Romero J, Ramos JA (2005) Cannabinoids in neurodegeneration and neuroprotection. In: Mechoulam R (ed) Cannabinoids as therapeutics (MDT). Birkha\u00fcser, Switzerland, pp79\u2013109"},{"key":"4_CR7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/syn.10054","volume":"44","author":"I Lastres-Becker","year":"2002","unstructured":"Lastres-Becker I, Hansen HH, Berrendero F, de Miguel R, P\u00e9rez-Rosado A, Manzanares J, Ramos JA, Fern\u00e1ndez-Ruiz J (2002) Loss of cannabinoid CB1 receptors and alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington\u2019s disease. Synapse 44:23\u201335","journal-title":"Synapse"},{"key":"4_CR8","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1046\/j.1471-4159.2003.01595.x","volume":"84","author":"I Lastres-Becker","year":"2003","unstructured":"Lastres-Becker I, de Miguel R, De Petrocellis L, Makriyannis A, Di Marzo V, Fern\u00e1ndez-Ruiz J (2003) Compounds acting at the endocannabinoid and\/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington\u2019s disease. J Neurochem 84:1097\u20131109","journal-title":"J Neurochem"},{"key":"4_CR9","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.nbd.2004.10.015","volume":"18","author":"E Fern\u00e1ndez-Espejo","year":"2005","unstructured":"Fern\u00e1ndez-Espejo E, Caraballo I, Rodr\u00edguez de Fonseca F, El Banoua F, Ferrer B, Flores JA, Gal\u00e1n-Rodr\u00edguez B (2005) Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism. Neurobiol Dis 18:591\u2013601","journal-title":"Neurobiol Dis"},{"key":"4_CR10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.brainres.2005.12.014","volume":"1073\u20131074","author":"S Gonz\u00e1lez","year":"2006","unstructured":"Gonz\u00e1lez S, Scorticati C, Garc\u00eda-Arencibia M, de Miguel R, Ramos JA, Fern\u00e1ndez-Ruiz J (2006) Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson\u2019s disease. Brain Res 1073\u20131074:209\u2013219","journal-title":"Brain Res"},{"key":"4_CR11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S1471-4914(02)02276-1","volume":"8","author":"R Mechoulam","year":"2002","unstructured":"Mechoulam R, Panikashivili A, Shohami E (2002) Cannabinoids and brain injury: therapeutic implications. Trends Mol Med 8:58\u201361","journal-title":"Trends Mol Med"},{"key":"4_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/13543784.11.10.1365","volume":"11","author":"RI Grundy","year":"2002","unstructured":"Grundy RI (2002) The therapeutic potential of the cannabinoids in neuroprotection. Expert Opin Investig Drugs 11:1\u201310","journal-title":"Expert Opin Investig Drugs"},{"key":"4_CR13","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/01.wad.0000189053.25817.d6","volume":"19","author":"Y Akwa","year":"2005","unstructured":"Akwa Y, Allain H, Bentue-Ferrer D, Berr C, Bordet R, Geerts H, Nieoullon A, Onteniente B, Vercelletto M (2005) Neuroprotection and neurodegenerative diseases: from biology to clinical practice. Alzheimer Dis Assoc Disord 19:226\u2013239","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"4_CR14","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s001090000177","volume":"78","author":"M Guzm\u00e1n","year":"2001","unstructured":"Guzm\u00e1n M, S\u00e1nchez C, Galve-Roperh I (2001) Control of the cell survival\/death decision by cannabinoids. J Mol Med 78:613\u2013625","journal-title":"J Mol Med"},{"key":"4_CR15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.tips.2006.11.001","volume":"28","author":"J Fern\u00e1ndez-Ruiz","year":"2007","unstructured":"Fern\u00e1ndez-Ruiz J, Romero J, Velasco G, Tol\u00f3n RM, Ramos JA, Guzm\u00e1n M (2007) Cannabinoid CB2 receptor: a new target for the control of neural cell survival? Trends Pharmacol Sci 28:39\u201345","journal-title":"Trends Pharmacol Sci"},{"key":"4_CR16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0163-7258(02)00251-6","volume":"95","author":"HS Hansen","year":"2002","unstructured":"Hansen HS, Moesgaard B, Petersen G, Hansen HH (2002) Putative neuroprotective actions of N-acyl-ethanolamines. Pharmacol Ther 95:119\u2013126","journal-title":"Pharmacol Ther"},{"key":"4_CR17","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1385\/MN:26:2-3:317","volume":"26","author":"M Stelt van der","year":"2002","unstructured":"van der Stelt M, Veldhuis WB, Maccarrone M, Bar PR, Nicolay K, Veldink GA, Di Marzo V, Vliegenthart JF (2002) Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol Neurobiol 26:317\u2013346","journal-title":"Mol Neurobiol"},{"key":"4_CR18","doi-asserted-by":"crossref","first-page":"S327","DOI":"10.1007\/BF02562333","volume":"34","author":"HS Hansen","year":"1999","unstructured":"Hansen HS, Moesgaard B, Hansen HH, Schousboe A, Petersen G (1999) Formation of N-acyl-phosphatidylethanolamine and N-acylethanolamine (including anandamide) during glutamate-induced neurotoxicity. Lipids 34:S327\u2013S330","journal-title":"Lipids"},{"key":"4_CR19","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1046\/j.1471-4159.2001.00542.x","volume":"78","author":"HH Hansen","year":"2001","unstructured":"Hansen HH, Schmid PC, Bittigau P, Lastres-Becker I, Berrendero F, Manzanares J, Ikonomidou C, Schmid HH, Fernandez-Ruiz JJ, Hansen HS (2001) Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J Neurochem 78:1415\u20131427","journal-title":"J Neurochem"},{"key":"4_CR20","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1088208","volume":"302","author":"G Marsicano","year":"2003","unstructured":"Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, Azad SC, Cascio MG, Gutierrez SO, van der Stelt M, Lopez-Rodriguez ML, Casanova E, Schutz G, Zieglgansberger W, Di Marzo V, Behl C, Lutz B (2003) CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302:84\u201388","journal-title":"Science"},{"key":"4_CR21","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1523\/JNEUROSCI.22-16-06900.2002","volume":"22","author":"P Gubellini","year":"2002","unstructured":"Gubellini P, Picconi B, Bari M, Battista N, Calabresi P, Centonze D, Bernardi G, Finazzi-Agr\u00f2 A, Maccarrone M (2002) Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Neurosci 22:6900\u20136907","journal-title":"J Neurosci"},{"key":"4_CR22","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/35097089","volume":"413","author":"D Panikashvili","year":"2001","unstructured":"Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, Shohami E (2001) An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413:527\u2013531","journal-title":"Nature"},{"key":"4_CR23","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1161\/01.STR.0000023491.63693.18","volume":"33","author":"WR Schabitz","year":"2002","unstructured":"Schabitz WR, Giuffrida A, Berger C, Aschoff A, Schwaninger M, Schwab S, Piomelli D (2002) Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study. Stroke 33:2112\u20132124","journal-title":"Stroke"},{"key":"4_CR24","doi-asserted-by":"crossref","first-page":"8765","DOI":"10.1523\/JNEUROSCI.21-22-08765.2001","volume":"21","author":"M Stelt van der","year":"2001","unstructured":"van der Stelt M, Veldhuis WB, van Haaften GW, Fezza F, Bisogno T, B\u00e4r PR, Veldink GA, Vliegenthart JF, Di Marzo V, Nicolay K (2001) Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J Neurosci 21:8765\u20138771","journal-title":"J Neurosci"},{"key":"4_CR25","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/1531-8249(200008)48:2<257::AID-ANA18>3.0.CO;2-P","volume":"48","author":"KL Jin","year":"2000","unstructured":"Jin KL, Mao XO, Goldsmith PC, Greenberg DA (2000) CB1 cannabinoid receptor induction in experimental stroke. Ann Neurol 48:257\u2013261","journal-title":"Ann Neurol"},{"key":"4_CR26","doi-asserted-by":"crossref","first-page":"11136","DOI":"10.1523\/JNEUROSCI.23-35-11136.2003","volume":"23","author":"C Benito","year":"2003","unstructured":"Benito C, Nu\u00f1ez E, Tolon RM, Carrier EJ, Rabano A, Hillard CJ, Romero J. (2003) Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer\u2019s disease brains. J Neurosci 23:11136\u201311141","journal-title":"J Neurosci"},{"key":"4_CR27","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1523\/JNEUROSCI.23-10-04127.2003","volume":"23","author":"WB Veldhuis","year":"2003","unstructured":"Veldhuis WB, van der Stelt M, Wadman MW, van Zadelhoff G, Maccarrone M, Fezza F, Veldink GA, Vliegenthart JF, Bar PR, Nicolay K, Di Marzo V (2003) Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: role of vanilloid receptors and lipoxygenases. J Neurosci 23:4127\u20134133","journal-title":"J Neurosci"},{"key":"4_CR28","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1124\/mol.54.3.459","volume":"54","author":"M Shen","year":"1998","unstructured":"Shen M, Thayer SA (1998) Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol Pharmacol 54:459\u2013462","journal-title":"Mol Pharmacol"},{"key":"4_CR29","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0304-3940(01)02065-1","volume":"309","author":"ME Abood","year":"2001","unstructured":"Abood ME, Rizvi G, Sallapudi N, McAllister SD (2001) Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci Lett 309:197\u2013201","journal-title":"Neurosci Lett"},{"key":"4_CR30","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1523\/JNEUROSCI.19-08-02987.1999","volume":"19","author":"T Nagayama","year":"1999","unstructured":"Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin KL, Greenberg DA (1999) Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 19:2987\u20132995","journal-title":"J Neurosci"},{"key":"4_CR31","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0165-6147(00)01805-8","volume":"22","author":"E Schlicker","year":"2001","unstructured":"Schlicker E, Kathmann M (2001) Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 22:565\u2013572","journal-title":"Trends Pharmacol Sci"},{"key":"4_CR32","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/00001756-200305060-00007","volume":"14","author":"I Lastres-Becker","year":"2003","unstructured":"Lastres-Becker I, Bizat N, Boyer F, Hantraye P, Brouillet E, Fern\u00e1ndez-Ruiz J (2003) Effects of cannabinoids in the rat model of Huntington\u2019s disease generated by an intrastriatal injection of malonate. Neuroreport 14:813\u2013816","journal-title":"Neuroreport"},{"key":"4_CR33","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1046\/j.1471-4159.2002.00961.x","volume":"82","author":"HH Hansen","year":"2002","unstructured":"Hansen HH, Azcoitia I, Pons S, Romero J, Garcia-Segura LM, Ramos JA, Hansen HS, Fernandez-Ruiz J (2002) Blockade of cannabinoid CB1 receptor function protects against in vivo disseminating brain damage following NMDA-induced excitotoxicity. J Neurochem 82:154\u2013158","journal-title":"J Neurochem"},{"key":"4_CR34","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/1098-2299(200007\/08)50:3\/4<211::AID-DDR3>3.0.CO;2-G","volume":"50","author":"E Shohami","year":"2000","unstructured":"Shohami E, Mechoulam R (2000) A non-psychotropic cannabinoid with neuroprotective properties. Drug Dev Res 50:211\u2013215","journal-title":"Drug Dev Res"},{"key":"4_CR35","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1471-4159.1998.70020671.x","volume":"70","author":"AJ Hampson","year":"1998","unstructured":"Hampson AJ, Bornheim LM, Scanziani M, Yost CS, Gray AT, Hansen BM, Leonoudakis DJ, Bickler PE (1998) Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. J Neurochem 70:671\u2013676","journal-title":"J Neurochem"},{"key":"4_CR36","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.lfs.2005.05.055","volume":"78","author":"DG Demuth","year":"2006","unstructured":"Demuth DG, Molleman A (2006) Cannabinoid signalling. Life Sci 78:549\u2013563","journal-title":"Life Sci"},{"key":"4_CR37","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0165-0173(02)00218-7","volume":"41","author":"CJ Fowler","year":"2003","unstructured":"Fowler CJ (2003) Plant-derived, synthetic and endogenous cannabinoids as neuroprotective agents. Non-psychoactive cannabinoids, \u2018entourage\u2019 compounds and inhibitors of N-acyl ethanolamine breakdown as therapeutic strategies to avoid pyschotropic effects. Brain Res Rev 41:26\u201343","journal-title":"Brain Res Rev"},{"key":"4_CR38","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s001090050287","volume":"76","author":"JA Wagner","year":"1998","unstructured":"Wagner JA, Varga K, Kunos G (1998) Cardiovascular actions of cannabinoids and their generation during shock. J Mol Med 76:824\u2013836","journal-title":"J Mol Med"},{"key":"4_CR39","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0163-7258(02)00258-9","volume":"95","author":"MD Randall","year":"2002","unstructured":"Randall MD, Harris D, Kendall DA, Ralevic V (2002) Cardiovascular effects of cannabinoids. Pharmacol Ther 95:191\u2013202","journal-title":"Pharmacol Ther"},{"key":"4_CR40","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/01.RES.87.4.323","volume":"87","author":"Y Chen","year":"2000","unstructured":"Chen Y, McCarron RM, Ohara Y, Bembry J, Azzam N, Lenz FA, Shohami E, Mechoulam R, Spatz M (2000) Human brain capillary endothelium: 2-arachidonoglycerol (endocannabinoid) interacts with endothelin-1. Circ Res 87:323\u2013327","journal-title":"Circ Res"},{"key":"4_CR41","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.pharmthera.2004.11.005","volume":"106","author":"M Begg","year":"2005","unstructured":"Begg M, Pacher P, Batkai S, Osei-Hyiaman D, Offertaler L, Mo FM, Liu J, Kunos G (2005) Evidence for novel cannabinoid receptors. Pharmacol Ther 106:133\u2013145","journal-title":"Pharmacol Ther"},{"key":"4_CR42","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/glia.20084","volume":"48","author":"N Stella","year":"2004","unstructured":"Stella N (2004) Cannabinoid signaling in glial cells. Glia 48:267\u2013277","journal-title":"Glia"},{"key":"4_CR43","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/sj.bjp.0705667","volume":"141","author":"L Walter","year":"2004","unstructured":"Walter L, Stella N (2004) Cannabinoids and neuroinflammation. Br J Pharmacol 141:775\u2013785","journal-title":"Br J Pharmacol"},{"key":"4_CR44","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0022-3565(24)39213-4","volume":"293","author":"SR Smith","year":"2000","unstructured":"Smith SR, Terminelli C, Denhardt G (2000) Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. J Pharmacol Exp Ther 293:136\u2013150","journal-title":"J Pharmacol Exp Ther"},{"key":"4_CR45","doi-asserted-by":"crossref","first-page":"6470","DOI":"10.1523\/JNEUROSCI.23-16-06470.2003","volume":"23","author":"F Molina-Holgado","year":"2003","unstructured":"Molina-Holgado F, Pinteaux E, Moore JD, Molina-Holgado E, Guaza C, Gibson RM, Rothwell NJ (2003) Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J Neurosci 23:6470\u20136474","journal-title":"J Neurosci"},{"key":"4_CR46","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0024-3205(99)00288-X","volume":"65","author":"M Guzman","year":"1999","unstructured":"Guzman M, Sanchez C (1999) Effects of cannabinoids on energy metabolism. Life Sci 65:657\u2013664","journal-title":"Life Sci"},{"key":"4_CR47","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1046\/j.0022-3042.2001.00716.x","volume":"80","author":"G Marsicano","year":"2002","unstructured":"Marsicano G, Moosmann B, Hermann H, Lutz B, Behl C (2002) Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J Neurochem 80:448\u2013456","journal-title":"J Neurochem"},{"key":"4_CR48","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0014-2999(95)00271-L","volume":"283","author":"N Eshhar","year":"1995","unstructured":"Eshhar N, Striem S, Kohen R, Tirosh O, Biegon A (1995) Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist. Eur J Pharmacol 283:19\u201329","journal-title":"Eur J Pharmacol"},{"key":"4_CR49","doi-asserted-by":"crossref","first-page":"8268","DOI":"10.1073\/pnas.95.14.8268","volume":"95","author":"AJ Hamson","year":"1998","unstructured":"Hampson AJ, Grimaldi M, Axelrod J, Wink D (1998) Cannabidiol and (\u2212)\u03949-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 95:8268\u20138273","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4_CR50","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0022-3565(24)39301-2","volume":"293","author":"Y Chen","year":"2000","unstructured":"Chen Y, Buck J (2000) Cannabinoids protect cells from oxidative cell death: a receptor-independent mechanism. J Pharmacol Exp Ther 293:807\u2013812","journal-title":"J Pharmacol Exp Ther"},{"key":"4_CR51","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.brainres.2006.11.063","volume":"1134","author":"M Garc\u00eda-Arencibia","year":"2007","unstructured":"Garc\u00eda-Arencibia M, Gonz\u00e1lez S, de Lago E, Ramos JA, Mechoulam R, Fern\u00e1ndez-Ruiz J (2007) Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson\u2019s disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res 1134:162\u2013170","journal-title":"Brain Res"},{"key":"4_CR52","doi-asserted-by":"crossref","unstructured":"Sagredo O, Ramos JA, Decio A, Mechoulam R, Fern\u00e1ndez-Ruiz J (2007) Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid receptors. Eur J Neurosci (in press)","DOI":"10.1111\/j.1460-9568.2007.05717.x"},{"key":"4_CR53","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1007\/s00018-006-6242-0","volume":"63","author":"M Borrell-Pages","year":"2006","unstructured":"Borrell-Pages M, Zala D, Humbert S, Saudou F (2006) Huntington\u2019s disease: from huntingtin function and dysfunction to therapeutic strategies. Cell Mol Life Sci 63:2642\u20132660","journal-title":"Cell Mol Life Sci"},{"key":"4_CR54","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1523\/JNEUROSCI.11-02-00563.1991","volume":"11","author":"M Herkenham","year":"1991","unstructured":"Herkenham M, Lynn AB, Little MD, Melvin LS, Johnson MR, de Costa DR, Rice KC (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11:563\u2013583","journal-title":"J Neurosci"},{"key":"4_CR55","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2174\/1568007033482751","volume":"2","author":"I Lastres-Becker","year":"2003","unstructured":"Lastres-Becker I, De Miguel R, Fern\u00e1ndez-Ruiz J (2003) The endocannabinoid system and Huntington\u2019s disease. Curr Drug Target CNS Neurol Disord 2:335\u2013347","journal-title":"Curr Drug Target CNS Neurol Disord"},{"key":"4_CR56","first-page":"2375","volume":"1","author":"I Lastres-Becker","year":"20045","unstructured":"Lastres-Becker I, Bizat N, Boyer F, Hantraye P, Fern\u00e1ndez-Ruiz JJ, Brouillet E (2004) Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo: implication for Huntington\u2019s disease. Neuroreport 15:2375\u20132379","journal-title":"Neuroreport"},{"key":"4_CR57","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.neuropharm.2006.06.013","volume":"51","author":"A Pintor","year":"2006","unstructured":"Pintor A, Tebano MT, Martire A, Grieco R, Galluzzo M, Scattoni ML, Pezzola A, Coccurello R, Felici F, Cuomo V, Piomelli D, Calamandrei G, Popoli P (2006) The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum. Neuropharmacology 51:1004\u20131012","journal-title":"Neuropharmacology"},{"key":"4_CR58","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0306-4522(00)00008-7","volume":"97","author":"M Glass","year":"2000","unstructured":"Glass M, Dragunow M, Faull RLM (2000) The pattern of neurodegeneration in Huntington\u2019s disease: a comparative study of cannabinoid, dopamine, adenosine and GABA-A receptor alterations in the human basal ganglia in Huntington\u2019s disease. Neuroscience 97:505\u2013519","journal-title":"Neuroscience"},{"key":"4_CR59","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0006-8993(01)03403-5","volume":"929","author":"I Lastres-Becker","year":"2002","unstructured":"Lastres-Becker I, Berrendero F, Lucas JJ, Martin E, Yamamoto A, Ramos JA, Fern\u00e1ndez-Ruiz J (2002) Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington\u2019s disease. Brain Res 929:236\u2013242","journal-title":"Brain Res"},{"key":"4_CR60","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0306-4522(00)00157-3","volume":"98","author":"EM Denovan-Wright","year":"2000","unstructured":"Denovan-Wright EM, Robertson HA (2000) Cannabinoid receptor messenger RNA levels decrease in subset neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington\u2019s disease mice. Neuroscience 98:705\u2013713","journal-title":"Neuroscience"},{"key":"4_CR61","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.nbd.2004.04.001","volume":"16","author":"CT Aiken","year":"2004","unstructured":"Aiken CT, Tobin AJ, Schweitzer ES (2004) A cell-based screen for drugs to treat Huntington\u2019s disease. Neurobiol Dis 16:546\u2013555","journal-title":"Neurobiol Dis"},{"key":"4_CR62","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.nbd.2005.03.026","volume":"20","author":"W Wang","year":"2005","unstructured":"Wang W, Duan W, Igarashi S, Morita H, Nakamura M, Ross CA (2005) Compounds blocking mutant huntingtin toxicity identified using a Huntington\u2019s disease neuronal cell model. Neurobiol Dis 20:500\u2013508","journal-title":"Neurobiol Dis"},{"key":"4_CR63","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/ana.410390317","volume":"39","author":"M Gu","year":"1996","unstructured":"Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AH (1996) Mitochondrial defect in Huntington\u2019s disease caudate nucleus. Ann Neurol 39:385\u2013389","journal-title":"Ann Neurol"},{"key":"4_CR64","doi-asserted-by":"crossref","first-page":"43245","DOI":"10.1074\/jbc.M305057200","volume":"278","author":"N Bizat","year":"2003","unstructured":"Bizat N, Hermel JM, Humbert S, Jacquard C, Creminon C, Escartin C, Saudou F, Krajewski S, Hantraye P, Brouillet E (2003) In vivo calpain\/caspase cross-talk during 3-nitropropionic acid-induced striatal degeneration: implication of a calpain-mediated cleavage of active caspase-3. J Biol Chem 278:43245\u201343253","journal-title":"J Biol Chem"},{"key":"4_CR65","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.nbd.2003.09.013","volume":"15","author":"MC Galas","year":"2004","unstructured":"Galas MC, Bizat N, Cuvelier L, Bantubungi K, Brouillet E, Schiffmann SN, Blum D (2004) Death of cortical and striatal neurons induced by mitochondrial defect involves differential molecular mechanisms. Neurobiol Dis 15:152\u2013159","journal-title":"Neurobiol Dis"},{"key":"4_CR66","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/sj.bjp.0705662","volume":"141","author":"S Toulmond","year":"2004","unstructured":"Toulmond S, Tang K, Bureau Y, Ashdown H, Degen S, O\u2019Donnell R, Tam J, Han Y, Colucci J, Giroux A, Zhu Y, Boucher M, Pikounis B, Xanthoudakis S, Roy S, Rigby M, Zamboni R, Robertson GS, Ng GY, Nicholson DW, Fluckiger JP (2004) Neuroprotective effects of M826, a reversible caspase-3 inhibitor, in the rat malonate model of Huntington\u2019s disease. Br J Pharmacol 141:689\u2013697","journal-title":"Br J Pharmacol"},{"key":"4_CR67","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/jnen\/60.2.161","volume":"60","author":"E Sapp","year":"2001","unstructured":"Sapp E, Kegel KB, Aronin N, Hashikawa T, Uchiyama Y, Tohyama K, Bhide PG, Vonsattel JP, DiFiglia M (2001) Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol 60:161\u2013172","journal-title":"J Neuropathol Exp Neurol"},{"key":"4_CR68","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/archpsyc.55.3.215","volume":"55","author":"G Rajkowska","year":"1998","unstructured":"Rajkowska G, Selemon LD, Goldman-Rakic PS (1998) Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. Arch Gen Psychiatry 55:215\u2013224","journal-title":"Arch Gen Psychiatry"},{"key":"4_CR69","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0301-0082(99)00067-2","volume":"62","author":"F Blandini","year":"2000","unstructured":"Blandini F, Nappi G, Tassorelli C, Martignoni E (2000) Functional changes in the basal ganglia circuitry in Parkinson\u2019s disease. Prog Neurobiol 62:63\u201388","journal-title":"Prog Neurobiol"},{"key":"4_CR70","first-page":"83","volume":"86","author":"PL McGeer","year":"2001","unstructured":"McGeer PL, Yasojima K, McGeer EG (2001) Inflammation in Parkinson\u2019s disease. Adv Neurol 86:83\u201389","journal-title":"Adv Neurol"},{"key":"4_CR71","first-page":"657","volume":"2","author":"TB Sherer","year":"2001","unstructured":"Sherer TB, Betarbet R, Greenamyre JT (2001) Pathogenesis of Parkinson\u2019s disease. Curr Opin Investig Drugs 2:657\u2013662","journal-title":"Curr Opin Investig Drugs"},{"key":"4_CR72","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/00019052-200208000-00009","volume":"15","author":"KD Sethi","year":"2002","unstructured":"Sethi KD (2002) Clinical aspects of Parkinson disease. Curr Opin Neurol 15:457\u2013460","journal-title":"Curr Opin Neurol"},{"key":"4_CR73","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s007020200064","volume":"109","author":"A Carlsson","year":"2002","unstructured":"Carlsson A (2002) Treatment of Parkinson\u2019s with L-DOPA. The early discovery phase, and a comment on current problems. J Neural Transm 109:777\u2013787","journal-title":"J Neural Transm"},{"key":"4_CR74","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1006\/nbdi.1998.0220","volume":"5","author":"P Consroe","year":"1998","unstructured":"Consroe P (1998) Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol Dis 5:534\u2013551","journal-title":"Neurobiol Dis"},{"key":"4_CR75","first-page":"23","volume":"6","author":"KR M\u00fcller-Vahl","year":"1999","unstructured":"M\u00fcller-Vahl KR, Kolbe H, Schneider U, Emrich HM (1999). Cannabis in movement disorders. Forsch Komplementmed 6:23\u201327","journal-title":"Forsch Komplementmed"},{"key":"4_CR76","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.nbd.2004.11.009","volume":"19","author":"I Lastres-Becker","year":"2005","unstructured":"Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fern\u00e1ndez-Ruiz J (2005) Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson\u2019s disease. Neurobiol Dis 19:96\u2013107","journal-title":"Neurobiol Dis"},{"key":"4_CR77","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1046\/j.1471-4159.2002.00928.x","volume":"81","author":"HM Gao","year":"2002","unstructured":"Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B (2002) Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson\u2019s disease. J Neurochem 81:1285\u20131297","journal-title":"J Neurochem"},{"key":"4_CR78","doi-asserted-by":"crossref","first-page":"6309","DOI":"10.1523\/JNEUROSCI.20-16-06309.2000","volume":"20","author":"WG Kim","year":"2000","unstructured":"Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B, Hong JS (2000) Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci 20:6309\u20136316","journal-title":"J Neurosci"},{"key":"4_CR79","first-page":"277","volume":"60","author":"T Nagatsu","year":"2000","unstructured":"Nagatsu T, Mogi M, Ichinose H, Togari A (2000) Changes in cytokines and neurotrophins in Parkinson\u2019s disease. J Neural Transm 60:277\u2013290","journal-title":"J Neural Transm"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-007-0004-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12035-007-0004-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-007-0004-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T08:29:59Z","timestamp":1737102599000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12035-007-0004-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,23]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["4"],"URL":"https:\/\/doi.org\/10.1007\/s12035-007-0004-3","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,23]]}}}